München
25.04.25
08:11 Uhr
0,707 Euro
0,000
0,00 %
0,00 %
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | DIAMYD MEDICAL AB: Shareholders in Diamyd Medical, including the Chairman of the Board, have provided additional subscription commitments in the ongoing rights issue | 2 | Cision News | ||
| DIAMYD MEDICAL Aktie jetzt für 0€ handeln | |||||
| Mo | Diamyd Medical AB: Diamyd Medical highlights opportunity in Type 1 Diabetes prevention, adult-onset market, and upcoming Phase 3 readout | 235 | PR Newswire | STOCKHOLM, April 21, 2025 /PRNewswire/ -- In a recent investor interview, Diamyd Medical Board Member Professor Mark Atkinson and CEO Ulf Hannelius shared key insights into the Company's... ► Artikel lesen | |
| 17.04. | DIAMYD MEDICAL AB: The prevention trial DiaPrecise with Diamyd® clears first safety milestone | 1 | Cision News | ||
| 15.04. | DIAMYD MEDICAL AB: Australia grants Diamyd Medical patent for novel antigen combination in autoimmune diabetes treatment | 4 | Cision News | ||
| 15.04. | Diamyd Medical AB (publ): Australia grants Diamyd Medical patent for novel antigen combination in autoimmune diabetes treatment | 102 | GlobeNewswire (Europe) | The Australian Patent Office has granted a patent protecting a novel immunotherapeutic composition developed by Diamyd Medical for use in the treatment and prevention of autoimmune diabetes. The patent... ► Artikel lesen | |
| 14.04. | DIAMYD MEDICAL AB: Diamyd Medical publishes prospectus with regards to the rights issue | 1 | Cision News | ||
| 09.04. | Diamyd Medical AB (publ): Quarterly Report 2 24/25 | 88 | GlobeNewswire (Europe) | Diamyd Medical today announces in its second quarterly report for fiscal year 2024/2025 continued progress toward a transformative regulatory milestone, with early Phase 3 results from the DIAGNODE-3... ► Artikel lesen | |
| 09.04. | XFRA CAPITAL ADJUSTMENT INFORMATION - 09.04.2025 | 114 | Xetra Newsboard | Das Instrument N7S CA87043J2039 SWEET POISON SPIRITS INC. EQUITY wird cum Kapitalmassnahme gehandelt am 09.04.2025 und ex Kapitalmassnahme am 10.04.2025 The instrument N7S CA87043J2039 SWEET POISON... ► Artikel lesen | |
| 21.03. | DIAMYD MEDICAL AB: Diamyd Medical announces additional subscription commitments for upcoming rights issue | 1 | Cision News | ||
| 17.03. | DIAMYD MEDICAL AB: Diamyd Medical highlights clinical benefits of C-peptide preservation at ATTD 2025 | 1 | Cision News | ||
| 13.03. | Diamyd Medical AB (publ): Diamyd Medical advances AI-powered screening for Type 1 Diabetes within the ASSET Project | 123 | GlobeNewswire (Europe) | Diamyd Medical, in collaboration with Mainly AI and ASSET partners, highlights meaningful progress in AI-driven screening and risk prediction for Type 1 Diabetes at the Advanced Technologies & Treatments... ► Artikel lesen | |
| 10.03. | DIAMYD MEDICAL AB: Diamyd Medical announces additional subscription commitments for upcoming rights issue | 3 | Cision News | ||
| 28.02. | DIAMYD MEDICAL AB: The Board of Directors in Diamyd Medical has resolved on a rights issue of approximately SEK 208 million | 3 | Cision News | ||
| 20.02. | DIAMYD MEDICAL AB: Diamyd Medical precision medicine patent for prevention and treatment of autoimmune diabetes to be granted in Mexico | 2 | Cision News | ||
| 18.02. | Diamyd Medical AB (publ): Diamyd Medical's CFO to leave in 2025 | 102 | GlobeNewswire (Europe) | Diamyd Medical announced today that Anna Styrud, CFO, has decided to step down from her position. During her 15 years as CFO, she has successfully navigated the financial markets and played a key role... ► Artikel lesen | |
| 12.02. | Diamyd Medical AB: Diamyd Medical announces expanded financial support from Breakthrough T1D | 385 | PR Newswire | STOCKHOLM, Feb. 12, 2025 /PRNewswire/ -- Diamyd Medical will receive USD 1.75 million in expanded collaboration support from Breakthrough T1D (formerly JDRF), the world's leading Type 1 Diabetes... ► Artikel lesen | |
| 29.01. | Diamyd Medical AB (publ): Quarterly Report 1 24/25 | 75 | GlobeNewswire (Europe) | September 2024 - November 2024, Diamyd Medical AB (publ), Fiscal year 2024/2025
Precision Medicine for Autoimmune Diabetes
Aiming for Accelerated Market Approval
Diamyd Medical's B-share is traded... ► Artikel lesen | |
| 21.01. | DIAMYD MEDICAL AB: South Korea to grant precision medicine patent to Diamyd Medical for insulin antigen treatment in autoimmune diabetes | 2 | Cision News | ||
| 13.01. | Diamyd Medical AB: Diamyd Medical updates U.S. market potential for Diamyd | 386 | PR Newswire | STOCKHOLM, Jan. 13, 2025 /PRNewswire/ -- Diamyd Medical has released an updated analysis of the commercial potential for its lead product candidate, the precision immunotherapy Diamyd® (rhGAD65/alum)... ► Artikel lesen | |
| 10.01. | Diamyd Medical AB: Diamyd Medical confirms key advances toward Accelerated Approval for Diamyd following FDA Type C Meeting | 1.406 | PR Newswire | STOCKHOLM, Jan. 10, 2025 /PRNewswire/ -- Diamyd Medical provides an update following the receipt of final meeting minutes from a positive Type C meeting with the U.S. Food and Drug Administration... ► Artikel lesen |
Seite:
1 2 Weiter >>
39 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ABBVIE | 160,40 | +1,13 % | AbbVie Aktie: Zwischen Hoffnung und Skepsis | AbbVie-Aktie legt zu, doch Experten bewerten unterschiedlich. Neue Medikamente sollen Humira-Verluste ausgleichen. Bleibt die Erwartungshaltung realistisch? Analysten gespaltenAnzeigeSollten Anleger... ► Artikel lesen | |
| INNOCAN PHARMA | 0,104 | -1,89 % | InnoCan Pharma Aktie: Kapitalspritze mit Beigeschmack | InnoCan Pharma schließt Privatplatzierung ab, doch die Finanzspritze könnte bestehende Aktionäre verwässern. Der Aktienkurs fällt weiter. Die Aktie von InnoCan Pharma verliert heute deutlich und notiert... ► Artikel lesen | |
| ABBOTT LABORATORIES | 114,16 | +0,44 % | Medtronic plc: Medtronic advances Abbott CGM partnership with FDA submission of interoperable insulin pump | GALWAY, Ireland, April 24, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced it has submitted 510(k)... ► Artikel lesen | |
| ARZNEIWERK AG VIDA | 0,482 | 0,00 % | PTA-AFR: Arzneiwerk AG VIDA: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114-117 WpHG | DJ PTA-AFR: Arzneiwerk AG VIDA: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114-117 WpHG
Vorabbekanntmachung Finanzberichte gemäß ---- 114-117 WpHG
Arzneiwerk... ► Artikel lesen | |
| ZOETIS | 134,10 | +0,25 % | Dividendenbekanntmachungen (21.04.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) BANK OF NEW YORK MELLON CORPORATION US0640581007 0,47 USD 0,4125 EUR BANK PERMATA TBK ID1000098205 30 IDR 0,0015 EUR BANK PERMATA... ► Artikel lesen | |
| CRESCO LABS | 0,685 | -0,51 % | Cresco Labs Aktie: Komplexe Lage droht? | Cresco Labs verzeichnete im Geschäftsjahr 2024 eine beeindruckende finanzielle Entwicklung mit einem Jahresumsatz von 724 Millionen Euro. Trotz dieser positiven Kennzahlen schloss das Unternehmen mit... ► Artikel lesen | |
| CSPC PHARMA | 0,686 | -3,08 % | CSPC PHARMA (01093): UNAUDITED FINANCIAL INFORMATION OF CSPC INNOVATION PHARMACEUTICAL CO., LTD. FOR THE THREE MONTHS ENDED 31 MARCH 2025 | ||
| TONIX PHARMACEUTICALS | 15,100 | 0,00 % | Tonix Pharmaceuticals Holding Corp.: Tonix Pharmaceuticals Presented Data on Potential Mpox Vaccine TNX-801 at World Vaccine Congress Washington 2025 | ||
| AMARIN | 11,040 | 0,00 % | XFRA EH3: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILAMARIN CORP.ADR... ► Artikel lesen | |
| NEKTAR THERAPEUTICS | 0,629 | -2,86 % | Nektar Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results | SAN FRANCISCO, March 12, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the fourth quarter ended December 31, 2024.
Cash... ► Artikel lesen | |
| AXSOME THERAPEUTICS | 92,28 | -0,30 % | Axsome Aktie: Riskante Talfahrt? | Große Investoren erhöhen ihre Anteile an Axsome Therapeutics deutlich, während eine Sammelklage Unsicherheit schafft. Wie wirkt sich das auf die Aktie aus? Die Aktie von Axsome Therapeutics sorgt für... ► Artikel lesen | |
| WUXI BIOLOGICS | 2,631 | +2,37 % | WuXi Biologics-Aktie heute am Aktienmarkt gefragt (2,665 €) | An der Börse notiert die Aktie von WuXi Biologics gegenwärtig fester. Das Wertpapier notiert zur Stunde bei 2,67 Euro. Jahreschart der WuXi Biologics Inc-Aktie, Stand 25.04.2025 Freuen können sich gegenwärtig... ► Artikel lesen | |
| JAGUAR HEALTH | 8,010 | 0,00 % | Jaguar Health, Inc. - 8-K, Current Report | ||
| ACADIA PHARMACEUTICALS | 13,130 | +0,77 % | Acadia Pharmaceuticals Inc.: Acadia Pharmaceuticals and Saniona Announce Initial Positive Results from ACP-711 (formerly SAN711) Phase 1 Study | Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) and Saniona (OMX: SANION) today announced the successful completion of the two originally planned cohorts in their Phase 1 multiple-ascending-dose MAD study... ► Artikel lesen | |
| DAIICHI SANKYO | 21,850 | +2,53 % | Daiichi Sankyo Company Limited Bottom Line Advances In Full Year | TOKYO (dpa-AFX) - Daiichi Sankyo Company Limited (DSKYF.PK) revealed a profit for its full year that increased from the same period last yearThe company's bottom line totaled JPY295.756 billion... ► Artikel lesen |
Das Unternehmen DIAMYD MEDICAL AB kann der Branche Pharma zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,707 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu DIAMYD MEDICAL AB finden Sie auf Wallstreet Online.
